The Board
Dr Anthony Martin, Non-Executive Chairman
Dr Martin has a long history of creating substantial value in the life sciences arena. Dr Martin is currently Chairman of Wound Solutions Ltd, Safeguard Biosystems Holdings Ltd, 1Voice1Vision Ltd and, until December 2009, a director of Molecular Insight Pharmaceuticals Inc, a NASDAQ-listed biopharmaceutical company. Previously he has been Chairman of NeuTec Pharma plc, President and CEO of Molecular Probes Inc., President of Molecular Biology for Invitrogen Corporation and President and CEO of Invitrogen B.V. Between 1995 and 2000 he was Chairman and CEO of AZUR Environmental Inc. Before that, he was Chief Executive of Celsis International plc and Chairman of Tepnel Life Sciences plc.
Dr Stuart Hendry, CEO, Director
Dr Hendry has 20 years' experience in the medical device industry having been CEO of Sphere since its founding in 2002. Prior to Sphere he held positions at the Generics Group plc, PowderJect plc, Diametrics Inc and Pfizer Hospital Products. He has been instrumental in the commercialisation of numerous medical devices mainly in the area of clinical monitoring and diagnostics. He is on the board of ERBI Ltd, is chairman of the Medilink Steering Group, a member of the CBI SME Council, a member of the Healthcare KTN Steering Group and is on the Industry Advisory Board of BNC Ltd. He holds a doctorate in biosensor technology and is author on numerous patents, scientific and medical publications in the area of clinical diagnostics and monitoring.
Dr Ann Simon, Chief Financial Officer
Dr Simon has worked in finance, particularly in the healthcare and technology sectors, since 1985. Over the last decade she has been CFO of Genosis PLC, Mirada Solutions, NextGen Sciences, e-San and Bioglan Pharma. She has managed IPOs (London full list and AIM), corporate acquisitions and trade sales and fund raisings in the public and private markets. Prior to that she did corporate finance advisory work at Cazenove & Co. for clients ranging from start-ups to FTSE100 companies. She was on the FSA’s Financial Information Theme Team from 2002 to 2003. She is also a non-executive director of Scientific Digital Imaging PLC.
Richard P Lyman, Non-Executive Director
Oakes Lyman & Co.
Mr Lyman is a Managing Director of Oakes, Lyman & Co. Limited. Additionally, in his corporate career he was President of Squibb's Medical Systems International Group. In his career in venture capital he formed a number of start-up companies including Biotechnology General Inc. (where he was Chairman and CEO), Life Technologies - now Invitrogen Corporation (Chairman and CEO), Medimmune Inc (Director), Genetic Therapy Inc. (Chairman), Osteotech Inc. (Chairman) and Quadrant Healthcare plc (Chairman and CEO).
Dr William Mason, Non-Executive Director
Dr Mason has a PhD in Physiology from Cambridge University. He is a Director of several UK and US high technology private and/or publicly quoted companies in healthcare and biosciences. He has considerable experience in the public and private sectors, including the successful commercial development, creation of shareholder value and value realization of high technology life science- and healthcare- focused industries. He has been actively involved with a number of IPOs and secondary fundings in public markets (LSE, NASDAQ) in addition to numerous funding activities for private equity companies. He founded Sage Healthcare, a specialist boutique for bio and health transactions based in US and Europe. He is a Member of the 3i plc Independent Directors Programme.
Bob Pettigrew, Non-Executive Director
Mr Pettigrew has more than 20 years experience in the development of emerging businesses. In 1986 he co-founded Generics (now Sagentia) and was key in its flotation in 2000. He was involved in developing Generics’ investment activities in early stage technology ventures and was a director of Generics Asset Management. He retired from Generics in 2002. He is an investor director in Zinwave, Timberpost and chairman of Acal Energy. He was Chairman of Voxar Ltd and managed its $50m trade sale in 2004. He is on the advisory boards of Antenova and the Synergy Fund and is a non-executive director of two listed VCTs.
Ian Paling, Non-Executive Director
Mr Paling has extensive experience of working at senior executive levels within the medical devices sector. He was CEO of Corin Group PLC until 2007, having been with the company through private ownership and then leading a highly successful IPO on the main market of the London Stock Exchange in 2002. While at Corin, he was instrumental in securing high profile distribution agreements, setting up profitable overseas subsidiaries and directing an acquisition strategy. He is non-executive chairman of Inion OY, a non-executive director of Metalrax Group PLC and CEO of CellCoTec BV. He was awarded the Ernst & Young Entrepreneur of the Year Award for the southern region in 2006 and the LSE Techmark Mediscience Chief Executive of the Year in 2008. Throughout his career he has been involved in manufacturing environments, predominantly in the life sciences sector.
Quest Management NV, Non-Executive Director
Quest Management is an independent asset management company based in Belgium. It manages both private and public equity investments in European technology and lifesciences companies. Its lead fund is Quest for Growth a pan-European technology and life sciences fund listed on Euronext Brussels. Quest for Growth is a crossover fund, investing in both listed and non-listed companies. Quest for Growth focuses on European technology-based growth companies in sectors such as biotechnology, medical, health care, information technology, software, electronics, and special situations in other growth sectors. Quest Management is represented by Dr William Brooks, who has worked for over 20 years in the biotechnology industry. His experience covers active management within the industry as well as strategic and board level consulting. He has worked for and with leading companies advising on such issues as business development, technology assessment, financial strategy and M&A. He applies this to both the private equity and quoted portfolio of life sciences investments at Quest Management.
Audit Committee
The Audit Committee consists of Dr William Mason (Chairman), Ian Paling and Richard Lyman.
